We are live on ! Find out more
DNTH icon

Dianthus Therapeutics
DNTH

72 hedge funds and large institutions have $67.4M invested in Dianthus Therapeutics in 2022 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 17 increasing their positions, 24 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

30% more capital invested

Capital invested by funds: $51.9M → $67.4M (+$15.5M)

0.46% more ownership

Funds ownership: 4.84% → 5.3% (+0.46%)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

4% less funds holding

Funds holding: 75 → 72 (-3)

11% less first-time investments, than exits

New positions opened: 8 | Existing positions closed: 9

29% less repeat investments, than reductions

Existing positions increased: 17 | Existing positions reduced: 24

Holders
72
Holders Change
-3
Holders Change %
-4%
% of All Funds
1.24%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
8
Increased
17
Reduced
24
Closed
9
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
Janus Henderson Group
Janus Henderson Group
United Kingdom
+$6.18M
2
RCM
RA Capital Management
Massachusetts
+$6.14M
3
WP
Woodline Partners
California
+$636K
4
Millennium Management
Millennium Management
New York
+$376K
5
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$193K

Top Sellers

1
CC
Casdin Capital
New York
-$3.58M
2
JP Morgan Chase
JP Morgan Chase
New York
-$787K
3
Renaissance Technologies
Renaissance Technologies
New York
-$559K
4
GPP
Great Point Partners
Connecticut
-$258K
5
Federated Hermes
Federated Hermes
Pennsylvania
-$227K
Name Holding Trade Value Shares
Change 		Change in
Stake
Legal & General Group
76
Legal & General Group
United Kingdom
– -$3K -149 Closed
Bank of America
77
Bank of America
North Carolina
– +$246 +9 +450%
AF
78
Allworth Financial
California
– +$548 +20 New
1 2 3
4

DNTH Hedge Fund Activity: Q3 2022 in Review

72 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Dianthus Therapeutics (DNTH) for Q3 2022, worth a combined $67.4M — up 30% from $51.9M a quarter earlier.

Sellers outnumbered buyers: 9 funds closed out of DNTH and 8 opened new positions — a net loss of 1 holder — while 24 trimmed existing stakes and 17 added.

The largest buyer was Janus Henderson Group, adding an estimated $6.18M. The largest seller was Casdin Capital, cutting an estimated $3.58M.

  • 72 institutional investors held Dianthus Therapeutics (DNTH) as of Q3 2022, down from 75 in Q2 2022.
  • Funds reported $67.4M of Dianthus Therapeutics stock for Q3 2022, up 30% quarter-over-quarter.
  • 8 funds opened new Dianthus Therapeutics positions in Q3 2022 and 9 closed out, a net change of -1 holder.
  • The largest Dianthus Therapeutics buyer in Q3 2022 was Janus Henderson Group, an estimated $6.18M added.
  • The largest Dianthus Therapeutics seller in Q3 2022 was Casdin Capital, an estimated $3.58M sold.

Based on aggregated 13F filings for Q3 2022.